{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:40:47Z","timestamp":1777934447091,"version":"3.51.4"},"reference-count":27,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T00:00:00Z","timestamp":1587600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Describe temporal changes in use of myelosuppressive chemotherapy, primary prophylactic colony-stimulating factor, and neutropenia-related hospitalization, in commercially insured patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using a large commercial administrative database, we identified annual cohorts of adult patients diagnosed with breast or lung cancer, or non-Hodgkin lymphoma and initiating myelosuppressive chemotherapy during 2005\u20132017. We described yearly changes in proportions of myelosuppressive chemotherapy by febrile neutropenia risk category (high, intermediate, unclassified) and proportion of prophylactic colony-stimulating factor use and unadjusted incidence of neutropenia-related hospitalization in the first cycle of myelosuppressive chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Annual cohorts included 4383\u20135888 eligible patients during 2005\u20132017. The proportion of eligible patients aged\u2009\u2265\u200965\u2009years increased from 26.0% in 2005 to 58.2% in 2017. Myelosuppressive chemotherapy use with regimens with high risk for febrile neutropenia increased from 15.1% in 2005 to 31.0% in 2017; and regimens with intermediate risk for febrile neutropenia decreased from 63.7% to 48.1% in 2017. Prophylactic colony-stimulating factor use increased from 41.6% in 2005 to 54.3% in 2017. Crude incidence of neutropenia-related hospitalization for all cancers increased from 2.0% to 3.1%, with a substantial increase in neutropenia-related hospitalization observed among non-Hodgkin lymphoma patients (2.8% to 8.5%) during 2005\u20132017.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Among adult patients with breast and lung cancer, and non-Hodgkin lymphoma receiving myelosuppressive chemotherapy, use of regimens with high risk for febrile neutropenia increased, as did the use of prophylactic colony-stimulating factors after 2005. Incidence of neutropenia-related hospitalization increased slightly, particularly among non-Hodgkin lymphoma patients. Further studies are required to understand this increasing trend of neutropenia-related hospitalization, changing patient-level risk factors, and febrile neutropenia management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1078155220915772","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T23:05:41Z","timestamp":1587683141000},"page":"128-142","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Trends in use of primary prophylactic colony stimulating factors and neutropenia-related hospitalization in commercially insured patients receiving myelosuppressive chemotherapy in the United States: 2005\u20132017"],"prefix":"10.1177","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8924-7218","authenticated-orcid":false,"given":"Jennifer R","family":"Schenfeld","sequence":"first","affiliation":[{"name":"Center for Observational Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corina W","family":"Bennett","sequence":"additional","affiliation":[{"name":"Center for Observational Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuling","family":"Li","sequence":"additional","affiliation":[{"name":"Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy J","family":"DeCosta","sequence":"additional","affiliation":[{"name":"Center for Observational Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee R","family":"Jaramillo","sequence":"additional","affiliation":[{"name":"Simulstat, Solana Beach, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad L","family":"Gawade","sequence":"additional","affiliation":[{"name":"Center for Observational Research, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2020,4,23]]},"reference":[{"key":"bibr1-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.1660"},{"key":"bibr2-1078155220915772","doi-asserted-by":"publisher","DOI":"10.3816\/SCT.2003.n.002"},{"key":"bibr3-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25332"},{"key":"bibr4-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21847"},{"key":"bibr5-1078155220915772","first-page":"CD003039","author":"Mhaskar R","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr6-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8823"},{"key":"bibr7-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199107183250305"},{"key":"bibr8-1078155220915772","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0175"},{"key":"bibr9-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.102"},{"key":"bibr10-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq147"},{"key":"bibr11-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"bibr12-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2010.10.013"},{"key":"bibr13-1078155220915772","unstructured":"National Comprehensive Care Network Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae) Hematopoietic Growth Factors. 2019."},{"key":"bibr14-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04773-6"},{"key":"bibr15-1078155220915772","first-page":"678","volume":"16","author":"Ramsey SD","year":"2010","journal-title":"Am J Manag Care"},{"key":"bibr16-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3720-x"},{"key":"bibr17-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-016-3079-4"},{"key":"bibr18-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-017-3863-9"},{"key":"bibr19-1078155220915772","volume-title":"Pharmacoepidemiology","author":"Seeger J","year":"2012","edition":"5"},{"key":"bibr20-1078155220915772","unstructured":"Optum. Optum Clinformatics Data Mart, www.optum.com\/content\/dam\/optum\/resources\/productSheets\/Clinformatics_for_Data_Mart.pdf(accessed 10 October 2018)."},{"key":"bibr21-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1097\/01.mlr.0000182534.19832.83"},{"key":"bibr22-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwq433"},{"key":"bibr23-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)33137-4"},{"key":"bibr24-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0000000000000182"},{"key":"bibr25-1078155220915772","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.18-2-s41"},{"key":"bibr26-1078155220915772","doi-asserted-by":"publisher","DOI":"10.3747\/co.25.3839"},{"key":"bibr27-1078155220915772","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-13-60"}],"updated-by":[{"DOI":"10.1177\/1078155220936492","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T00:00:00Z","timestamp":1591833600000}}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220915772","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155220915772","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155220915772","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:22:50Z","timestamp":1777688570000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155220915772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,23]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1177\/1078155220915772"],"URL":"https:\/\/doi.org\/10.1177\/1078155220915772","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,23]]}}}